Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
PlexusDx is not affiliated with Agile Health and has no commercial relationship with the companies reviewed
Beyond the two primary proteins of focus in ADRD progression, glymphatic clearance also helps support removal of inflammatory markers to maintain the parenchymal environment and reduce neurotoxic load on neurons (Mogensen et al., 2021)
Our syringe conversion chart covers all common concentrations
This effect attenuates postprandial glucose excursions, though tachyphylaxis (reduced response over time) to this particular effect may occur with chronic GLP-1 receptor agonist therapy
Competitive Position Eli Lilly Market Cap: ~$885-930B 2025 Rev Growth: +40-50% Forward P/E: ~31 Positioning: Market leader, oral GLP-1 coming Novo Nordisk Market Cap: ~$204-215B 2025 Rev Growth: +30% Forward P/E: ~12 Positioning: Struggling with competition, stock down 60% from peak Pfizer Market Cap: ~$160B 2025 Rev Growth: Declining Forward P/E: ~12 Positioning: Lost Metsera bid to competition Key Advantages: Tirzepatide (Mounjaro/Zepbound) consistently outperforms Novo's semaglutide (Ozempic/Wegovy) in head-to-head trials First-mover advantage with oral GLP-1 (orforglipron) Manufacturing scale-up: $12.5B+ invested in new facilities (Virginia, Texas, Puerto Rico) Direct-to-consumer platform (LillyDirect) creating pricing flexibility Valuation & Price Targets Current Price: ~$990 Market Cap: ~$885-930B Valuation Framework 2025 Est
US$ 22.89
US$ 27.48
US$ 20.55
US$ 27.91
